Industry Focus

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

 

Direct download: 20170802_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT

1